Jack Wallace
Stock Analyst at Guggenheim
(3.20)
# 1,133
Out of 5,050 analysts
19
Total ratings
57.89%
Success rate
273.86%
Average return
Main Sectors:
Stocks Rated by Jack Wallace
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VEEV Veeva Systems | Maintains: Buy | $233 → $249 | $294.86 | -15.55% | 4 | Oct 1, 2024 | |
| HIMS Hims & Hers Health | Maintains: Buy | $15 → $17 | $41.03 | -58.57% | 4 | Feb 27, 2024 | |
| HCAT Health Catalyst | Upgrades: Buy | $14 | $2.83 | +394.70% | 3 | Jan 26, 2024 | |
| IQV IQVIA Holdings | Maintains: Buy | $253 → $220 | $210.46 | +4.53% | 1 | Nov 3, 2023 | |
| PHR Phreesia | Maintains: Buy | $35 → $40 | $22.02 | +81.65% | 5 | Mar 29, 2023 | |
| AMWL American Well | Reiterates: Buy | $100 | $4.21 | +2,275.30% | 1 | Mar 15, 2023 | |
| PINC Premier | Initiates: Neutral | n/a | $28.15 | - | 1 | Apr 14, 2022 |
Veeva Systems
Oct 1, 2024
Maintains: Buy
Price Target: $233 → $249
Current: $294.86
Upside: -15.55%
Hims & Hers Health
Feb 27, 2024
Maintains: Buy
Price Target: $15 → $17
Current: $41.03
Upside: -58.57%
Health Catalyst
Jan 26, 2024
Upgrades: Buy
Price Target: $14
Current: $2.83
Upside: +394.70%
IQVIA Holdings
Nov 3, 2023
Maintains: Buy
Price Target: $253 → $220
Current: $210.46
Upside: +4.53%
Phreesia
Mar 29, 2023
Maintains: Buy
Price Target: $35 → $40
Current: $22.02
Upside: +81.65%
American Well
Mar 15, 2023
Reiterates: Buy
Price Target: $100
Current: $4.21
Upside: +2,275.30%
Premier
Apr 14, 2022
Initiates: Neutral
Price Target: n/a
Current: $28.15
Upside: -